discovered over twenty years ago 1 , its extent and functional significance are only beginning to be fully understood. A major challenge has been the difficulty of detecting and studying the modification in vivo. Like other PTMs, O-GlcNAc is often dynamic, substoichiometric, targeted to specific subcellular compartments, and prevalent on lowabundance regulatory proteins 2, 3 . The sugar is also enzymatically and chemically labile, being subject to reversal by cellular glycosidases and cleavage on a mass spectrometer 2 .
As with many protein kinases, the lack of a well-defined consensus sequence for OGT has precluded the determination of in vivo modification sites based on primary sequence.
Here, we highlight some chemical approaches designed to overcome these challenges and advance a fundamental understanding of O-GlcNAc. beyond the reach of traditional methods (Fig. 2b) 
Rapid, sensitive detection

Mapping O-GlcNAc glycosylation sites
Mapping the sites of O-GlcNAc glycosylation within proteins is essential for elucidating the functional roles of O-GlcNAc in specific biological contexts.
Unfortunately, direct observation of the O-GlcNAc moiety by mass spectrometry during collision-induced dissociation (CID) is difficult as the glycosidic linkage is labile and readily cleaved, providing little peptide fragmentation 13 . Moreover, although OGT seems to favor sequences rich in proline, serine, and threonine residues 13 , there is no apparent consensus sequence that directs the action of OGT. The BEMAD strategy for mapping glycosylation sites. In this approach, the GlcNAc sugar undergoes a β-elimination reaction. Michael addition with dithiothreitol produces a sulfide adduct that is stable to MS/MS analysis.
A second approach capitalizes on the ability to selectively biotinylate O-GlcNAc proteins using ketone-or azido-containing UDP-galactose sugars as described above (Fig. 2) . In addition to isolating intact proteins, the biotin handle can be used to enrich O-GlcNAc peptides following proteolytic digestion 13 . This enrichment step is essential for mass spectrometric detection as the O-GlcNAc-modified species represents only a small fraction of the total peptides. Unlike BEMAD, the approach enables direct detection of the O-GlcNAc moiety by mass spectrometry, with the GlcNAcketogalactose-biotin tag providing a unique fragmentation pattern for unambiguous identification of O-GlcNAc peptides 13 . Notably, the strategy has been applied to both Together, proteome-wide studies have revealed that O-GlcNAc is a ubiquitous and abundant modification, with considerable functional significance and breadth. In less than 5 years, the number of known O-GlcNAc proteins in the brain has expanded from tens to hundreds, with many more proteins yet to be discovered.
Small molecule inhibitors of OGT and OGA
Historically, genetic manipulation of OGT and OGA activity in vivo has proven difficult. Whole animal and conditional deletions of the OGT gene have revealed that
OGT is essential for cell survival and mouse embryogenesis 23, 24 . Modulation of OGT using siRNA is complicated by the long half-life of the protein and often produces only partial knockdown of OGT 25 . Although deletion of OGA in C. elegans leads to metabolic changes and increased dauer formation 26 , no mammalian knockout of OGA has yet been reported. These features have challenged efforts to study O-GlcNAc glycosylation and have limited the use of conventional genetic tools to elucidate its role in cellular processes.
A complementary approach involves the generation of pharmacological agents to inhibit OGT and OGA. A well-established inhibitor of OGT, alloxan, exhibits multiple non-specific effects, such as inhibition of OGA 27 , glucokinase inhibition 28 , and formation of superoxide radicals 29 . By screening a 64,416-member library of compounds using a novel fluorescence-based assay, Gross and coworkers identified several promising new compounds that inhibit OGT activity in vitro (Fig. 4a, Compounds 1-3 ) 30 . These compounds were selective in inhibiting OGT but not another related enzyme MurG, which also uses UDP-GlcNAc as a substrate. Recently, a benzoxazolinone compound (Fig. 4a, Compound 1) was shown to inhibit OGT activity in oocytes where it prevents meiotic progression 31 . In the future, these numerous, chemically-distinct OGT inhibitors might be used in parallel to distinguish the potential non-specific effects of individual inhibitors in vivo.
As (Fig. 4b, Compounds 4-6 ) 34, 35 . In other studies, extending the N-acyl group of PUGNAc led to the creation of new inhibitors with greater than 10-fold selectivity for OGA over β-hexosaminidase 32, 36 . A drawback of these compounds is that they inhibit OGA more weakly than PUGNAc. In response to this problem, Dorfmeuller and coworkers designed a nagstatin derivative based on the crystal structure of NagJ, a bacterial homologue of human OGA (Fig. 4b, Compound 7) 
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. The isobutanamido group at the N8 position provides improved selectivity by fitting into a pocket that is larger than the corresponding pockets in other hexosaminidases, while the phenethyl group at the C2 position offered stronger inhibition (K i = 4.6 ± 0.1 pM) for the bacterial homologue of OGA by interacting with a solvent-exposed tryptophan residue. Nonetheless, a related nagstatin derivative still showed weaker inhibition toward human OGA than PUGNAc 38 .
More recently, Kim and coworkers designed a compound that strongly inhibits the short isoform of OGA (Fig. 4, Compound 8 ) 33 , an isoform that is only partially inhibited by 1 mM PUGNAc. However, selectivity may be an issue with this compound as thiosulphonate moieties have been shown to react with exposed cysteine residues of proteins 39 . Notably, compounds 4 and 7 have been tested in cell culture and were shown to increase overall cellular O-GlcNAc levels although none of these compounds were shown to have efficacy in vivo. Using a mechanism-inspired approach, Yuzwa and coworkers developed thiamet-G a nanomolar inhibitor (K i = 21 ± 3 nM) of OGA with low or no activity towards human lysosomal β-hexosaminidase and other glycoside hydrolases and, important, showed that it increases O-GlcNAc levels in the brain in vivo (Fig. 4b, Compound 9 close proximity, producing a stronger FRET signal (Fig. 5) . As anticipated, an increase in FRET (7-30%) was observed upon stimulation of transfected HeLa cells with PUGNAc and glucosamine. In the future, it will be interesting to examine changes in OGT activity in response to a variety of cellular stimuli.
In addition to monitoring OGT activity, identifying the intracellular signaling pathways and dynamics of O-GlcNAc glycosylation on specific protein substrates represents an important, challenging goal. General O-GlcNAc antibodies (CTD110.6 and RL-2) have been extremely valuable for measuring global changes in glycosylation in response to cellular stimuli 5, 6 . However, a limitation of these antibodies is that they detect only a small subset of the O-GlcNAc-modified proteins 8, 42 . Moreover, it remains difficult to identify the specific proteins that undergo changes in glycosylation. In From the time of its discovery, the appeal of O-GlcNAc has been both the intrigue of understanding its unique biology and the great technical challenges associated with its study. Over the last five years, we have seen a surge of new chemistry designed to meet these obstacles. Strengthened by an arsenal of chemical tools, the future of O-GlcNAc is primed for new and exciting discoveries.
